In this short video, Dr. Suresh Ramalingam discusses the rationale for targeting HER2 genetic aberrations in patients with NSCLC.

Take the Survey

Supported by an educational grant from Daiichi Sankyo.

Leave a Comment

Please confirm that you are not a robot.